Our data provided supports for additional studies toward the development of enhanced approaches for cancer treatment based on aberrant regulation of RAD51, which may become a potential predicative marker and therapeutic target in neoadjuvant endocrine therapy. The gene discussed is RAD51; the disease is cancer.